A004310 Stock Overview
Manufactures and distributes pharmaceutical products, health food drinks, and medical devices in South Korea and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Hyundai Pharmaceutical Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩3,690.00 |
| 52 Week High | ₩6,620.00 |
| 52 Week Low | ₩3,135.00 |
| Beta | 0 |
| 1 Month Change | 1.93% |
| 3 Month Change | -12.66% |
| 1 Year Change | -5.51% |
| 3 Year Change | -36.60% |
| 5 Year Change | -29.58% |
| Change since IPO | 333.64% |
Recent News & Updates
Recent updates
Shareholder Returns
| A004310 | KR Pharmaceuticals | KR Market | |
|---|---|---|---|
| 7D | 1.8% | 6.9% | 5.2% |
| 1Y | -5.5% | 8.1% | -4.3% |
Return vs Industry: A004310 underperformed the KR Pharmaceuticals industry which returned 8.1% over the past year.
Return vs Market: A004310 underperformed the KR Market which returned -4.3% over the past year.
Price Volatility
| A004310 volatility | |
|---|---|
| A004310 Average Weekly Movement | 7.0% |
| Pharmaceuticals Industry Average Movement | 5.6% |
| Market Average Movement | 6.7% |
| 10% most volatile stocks in KR Market | 12.8% |
| 10% least volatile stocks in KR Market | 3.4% |
Stable Share Price: A004310 has not had significant price volatility in the past 3 months compared to the KR market.
Volatility Over Time: A004310's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1965 | n/a | Sang-Jun Lee | www.hyundaipharm.co.kr |
Hyundai Pharmaceutical Co., Ltd. manufactures and distributes pharmaceutical products, health food drinks, and medical devices in South Korea and internationally. The company offers a range of ETC and OTC products in various therapeutic areas, including antianginal, antibiotic, antiemetics+antinauseants, antihistamines and antiallergics, antihyperlipidemic, antihypertensive, antiplatelet agent, antitussives, cell stimulants and proliferants, central nervous system, depilatory, dermatological agent, dermatology, dietary supplements, digestive system, endocrine system, expectorants, eye tonic and vitamins, gynaecolog antifungals, gynaecologic antiseptics, hemostatics, labour inhibitors, leukotriene modulator, narcotic analgesics, NSAIDs, oestrogens, ophthalmic products, OTH.sex horm and similar, SERMS, systemic hormonal contraceptives, urogenital system depilatory, uterotonic products, various alimentary tract and metabolism products, vitamins, acne, allergy, alopecia treatment, analgesics and anti-inflammatory, anemia, antimicrobial and antivirus, arthritis, contraceptives, dermatological agent, diagnostic reagent, gastrointestinal disorder and digestant, lip care, nutrition, ophthalmic product, respiratory, urogenital system, wound healing, and others. Hyundai Pharmaceutical Co., Ltd.
Hyundai Pharmaceutical Co., Ltd. Fundamentals Summary
| A004310 fundamental statistics | |
|---|---|
| Market cap | ₩102.13b |
| Earnings (TTM) | ₩1.41b |
| Revenue (TTM) | ₩108.14b |
0.0x
P/E Ratio0.0x
P/S RatioIs A004310 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A004310 income statement (TTM) | |
|---|---|
| Revenue | ₩108.14b |
| Cost of Revenue | ₩67.64b |
| Gross Profit | ₩40.49b |
| Other Expenses | ₩39.08b |
| Earnings | ₩1.41b |
Last Reported Earnings
Nov 30, 2013
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did A004310 perform over the long term?
See historical performance and comparisonDividends
0.9%
Current Dividend Yieldn/a
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/10 21:53 |
| End of Day Share Price | 2025/01/10 00:00 |
| Earnings | 2013/11/30 |
| Annual Earnings | 2013/11/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Hyundai Pharmaceutical Co., Ltd. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|